MRI protocol technique in the optimal therapeutic strategy of non-functioning pituitary adenomas

Gustavo Soto-Ares, Christine Cortet-Rudelli, Richard Assaker, Arnaud Boulinguez, C Dubest, Didier Dewailly and Jean Pierre Pruvo

Department of Neuroradiology, Hopital Roger Salengro, 1Department of Endocrinology, Clinic Marc Linquette and 2Department of Neurosurgery, Hopital Roger Salengro, Chru Lille, France

(Correspondence should be addressed to Gustavo Soto-Ares, Department of Neuroradiology, Hopital Roger Salengro, Chru Lille 59037, Lille, France; Email: gsotoares@chru-lille.fr)

Abstract

Objectives and Design: We performed a prospective study using magnetic resonance imaging (MRI) at regular post-operative intervals in non-irradiated patients with non-functioning pituitary adenomas (NFAs) to assess the frequency of tumoral regrowth and recurrences, in order to define the indications of post-operative radiotherapy.

Patients and Methods: Fifty-one patients aged 25–80 years (mean, 55.6±12.3 years) were included. Post-operative MRIs were performed 3–12 months (mean, 5.2±1.7 months) after surgery. 6 months later and then, every 12–18 months for at least 2 years. The mean post-operative follow-up was 67.7±31.8 months (range, 24–144 months).

Results: In 17 patients (33%, group I) no tumoral residue was observed on post-operative MRIs and no tumoral recurrence was diagnosed. Tumour regrowth was detected in 13 of the 34 patients (38.2%) with post-operative tumoral residue (group II), 7–66 months (mean, 27.3±17.3 months) after surgery. In this group, Kaplan–Meier analysis showed 78.8% recurrence free survival at 2 years and 60.9% at 5 years. Patients with tumoral regrowth had higher mean residual tumoral volume than patients without any tumoral regrowth in the group II (258±165 vs 163±165 mm3, P = 0.05).

Conclusions: We suggest a MRI protocol that includes, a 4- to 6-, 12- and 24-month post-operative MRI for every patient. When no tumoral residue is seen, pituitary radiotherapy is useless. MRI must be repeated 3, 5 and 10 years after surgery to eliminate late recurrence. The observed frequency of tumoral regrowth in patients with tumoral residue does not justify systematic post-operative radiotherapy. It should be performed only when tumoral regrowth is proved by a yearly MRI survey.
these patients, post-operative irradiation is indicated only when recurrence is proven.

To be able to determine the risk–benefit ratio of post-operative radiotherapy it is essential to establish the true frequency of post-operative tumoral regrowths and recurrences. We therefore performed a prospective study using MRI at regular follow-up intervals. Patients were scanned before and 3–7 months after surgery. This exam was then systematically repeated 6 months later and every 12–18 months thereafter. None of the patients observed in this study underwent systematic pituitary radiotherapy. We tried to identify factors that could predict recurrence or tumour regrowth in order to select patients who should receive radiotherapy.

**Patients and methods**

Fifty-one patients (22 males and 29 females) with clinically non-functioning pituitary adenoma, aged 25–80 years (mean, 55.6±12.3 years) were included. Trans-sphenoidal surgery was performed in 48 patients. One patient had trans-frontal surgery. The two surgical approaches were performed in two patients. None of them had systematic post-operative pituitary radiotherapy. Forty-one percent of the patients had headache. Loss of visual acuity and visual field defects were found in 56.9 and 90.2% of them, respectively. In 17.6% of the patients, the adenoma was diagnosed accidentally whilst undergoing MRI or CT scans for other indications. High plasma levels of a-subunit, follicle stimulating hormone (FSH) and/or luteinizing hormone (LH) levels were found in 13.7% of the patients. The immunostaining characteristics of the 48 evaluable adenomatous tissues were: gonadotrop (n = 29), non-functioning (n = 14) and silent corticotrop adenomas (n = 5). Gonadotrop, corticotrop and thyreotrop deficiency were diagnosed in 47.1, 43.1 and 27.5% of the patients, respectively.

Patients were scanned pre-operatively. The first post-operative MRI was performed at a mean of 5.2±1.7 months after surgery (at 3–4 months: n = 18; at 5–6 months: n = 27; at 7 months: n = 5; at 12 months: n = 1). The second scan was performed 6 months later and then repeated every 12–18 months.

**Figure 1** MRI findings in residual tumour. Coronal T1 (450/14/2) before surgery (a) shows an isointense mass with suprasellar extension and optic chiasma compression. In post-operative control (b), the residual tumour has the same signal characteristics. Note the hyperintensity of the surgical material at the left side of the sella.
for at least 2 years. The mean post-operative follow up was 67.7±31.8 months (range, 24–144 months). MRI has been available in our institution since 1990. Until 1994, the subjects were scanned with a 0.5 T Magnetom Vision imager using a standard head coil. After 1994, MRI examinations were performed in a 1T Magnetom Expert imager (Siemens, Erlangen, Germany). Imaging studies included sagittal T1-weighted (600/14/1: repetition time/echo time/ excitations) images and coronal T1- and TSE T2-weighted (4000/120/2) MR images. Coronal FLASH 2D dynamic series after contrast (180/4/1), were followed by sagittal and coronal post-contrast T1-weighted images. Every MRI was reviewed by two neuroradiologists, one neurosurgeon and two endocrinologists to assess invasion of sphenoidal, cavernous sinus and/or opto chiasmatic citerm in pre-operative scans, and to detect residual tumour and tumour regrowth in serial post-operative images. Invasion of cavernous sinus was diagnosed according to the classification proposed by Cottier et al. (16). Residual tumour was defined as a nodular mass with signal characteristics identical to those of the pre-operative adenomatous tissue. All cases with uncertain MRI diagnosis of residual tumour were included in the group of patients with residual tumour. Tumour regrowth was defined as an increase of the tumoral residue volume. Recurrence was defined by the appearance of adenomatous tissue with the same signal as the pre-operative mass in patients without any tumoral residue on the first post-operative MRI(s).

The choice of complementary treatment in cases of recurrences was made in multidisciplinary decision on a case-by-case basis.

Recurrence-free survival was measured by the actuarial method of Kaplan & Meier (17).

Results

MRI pre-operative features

In 82% of cases, the tumour was hypointense in T1-weighted images and hyperintense in T2. In the other cases, the tumours were isointense compared with the normal pituitary gland. The images of all the tumours were enhanced after contrast administration.

Figure 2 Residual tumour enhancement. Coronal T1-weighted image before (a) and after (b) contrast. In all cases, the image of the residual tumour is enhanced after contrast administration. The tumour is less enhanced than the pituitary stalk and the neurohypophysis.
Figure 3 Tumoral recurrence and regrowth. Coronal T1-weighted image before (a) and after (b) surgery. The volume of the residual tumour is important and recurrence at 6 (c) and 12 months (d) is progressive.
Figure 4 For legend, see next page.
Invasion of para-sellar structures included the sphenoidal sinus in 14% of the patients and the cavernous sinus in 45% patients. Eighty-eight percent of the patients had supra-sellar expansion.

MRI and residual tumour

Thirty-four patients (67%) had a tumoral residue on post-operative MRIs (Fig. 1a and b). In 93.5% of patients, the residual tumour was hypointense in T1-weighted images, after contrast administration the image was enhanced but less so than for the normal pituitary gland in all cases (Fig. 2a and b). Forty-five percent of the residual lesions had a heterogeneous signal in T2.

MRI and tumour recurrence

The mean follow-up was 67.7 ± 31.8 months (range, 24–144 months). Pituitary tumour regrowth occurred in 13/51 of patients (25.5%). The tumoral regrowth was detected at a mean of 27.3 ± 17.3 months (range, 7–66 months) after surgery. Kaplan–Meier analysis showed 86% tumoral regrowth-free survival at 2 years (95% confidence limits, 77–96%) and 74% at 5 years (95% confidence limits, 56–84%). The tumoral regrowth was asymptomatic in 9/13 patients (69%).

In 17 patients (33%, group I) no tumoral residue was found in post-operative MRIs. No tumoral recurrence was observed in this group. The frequency of tumoral regrowth was 38.2% in the group of patients with a post-operative tumoral residue (n = 34, group II). Kaplan–Meier analysis showed 78.8% recurrence-free survival at 2 years and 60.9% at 5 years in patients of the group II. The mean follow up was the same in the two groups (66.3 ± 33.9 vs 69.8 ± 30.6 months).

The neurosurgeon thought that surgical resection was complete for 25 patients but ten of them (40%) had a residual tumour on the post-operative MRIs. Two of these ten patients had subsequent tumour regrowth. Three patients with suspected incomplete resection had normal post-operative MRIs.

There was no significant relationship between tumoral regrowth and sex, age, immunostaining characteristics of the adenoma, the initial tumoral volume or the MRI signal of the tumour. Patients with tumoral regrowth had higher mean residual tumoral volume than patients without any tumoral regrowth in the group II (258 ± 165 vs 163 ± 165 mm³, P = 0.05) (Fig. 3a–d).

Complementary treatment

In cases with tumoral regrowth, 5/13 patients were operated on a second time (Fig. 4a–e); 4/13 patients were operated on and underwent subsequent radiotherapy; 3/13 patients underwent radiotherapy alone. Only one patient was medically treated because of poor clinical status and outcome.

Discussion

To our knowledge, this is the first prospective study evaluating the frequency of tumoral regrowth and recurrence in non-irradiated patients with NFAs, using MRI at regular post-operative follow-up intervals. We showed that tumoral regrowth was detected only among patients with a tumoral residue. The lesion was hypointense (93.5%) or isointense (6.5%) on T1-weighted images, with low enhancement after contrast administration when compared with normal pituitary gland on post-operative MRIs. A meticulous MRI technique is necessary to obtain a good delineation of the residual tumour and to demonstrate the tumoral regrowth. It consists of thin T1- and T2-weighted images obtained in coronal and sagittal planes (3 mm thick) with a high resolution technique, before and
after contrast administration. The post-operative mass effect can obscure remaining tumoral tissue and may alter the sensitivity of detection of residual tumour. Since stabilisation of the post-surgical changes occurs by the 4th month (18, 19), the optimal time to perform the first post-operative MRI should be 4–6 months after surgery. If the diagnosis of residual tumour is uncertain, MRI has to be repeated 6 and sometimes 12 months later, before concluding.

We demonstrated that surgeon assessment of complete tumoral removal was poor compared with MRI post-operative findings. Forty percent (\(n = 10\)) of the patients deemed to have macroscopic per-operative complete surgical removal (\(n = 25\)) were shown to have tumoral residue on post-operative MRIs. Two of them (20%) had subsequent tumoral regrowth. In this setting, our results clarify the statement of Turner et al. (2) who demonstrated that the surgeon’s assessment of complete surgical removal was unrelated to recurrence.

Tumoral regrowth-free survival at 5 years in our study seems to be comparable with results obtained by Turner et al. (2). However the mean delay of tumoral regrowth was 27.7±17.3 months in our series and 5.4 years in their study (2). Some of their patients had CT scans only, which is less reliable than MRI at detecting tumoral residue and/or recurrence. Moreover, there was no regular imaging follow-up. This could explain the longer delay in diagnosing recurrence observed by these authors. If our results are confirmed with a longer follow-up and a larger number of patients, it would suggest that yearly MRI allows earlier, more reliable diagnosis of tumoral regrowth. Tumoral regrowth has been reported to occur several years after surgery among non-irradiated patients with a post-operative adenomatous residue (1, 3, 4). So, yearly clinical and morphological follow-up has to be performed for life in these patients.

According to previous data, we found no significant relationship between tumoral regrowth and sex, age, immunostaining characteristics of the adenoma or initial tumoral volume. The volume of the residual tumour was the only morphological factor indicating more frequent recurrences.

We think that the frequency of recurrences observed in our study does not justify systematic immediate post-operative radiotherapy for all patients with post-operative adenomatous residue. Because of its potential complications, it should be performed only when tumoral regrowth is proven. However, if the adenomatous residue is voluminous and close to the optic nerves/chiasma, the indication of systematic post-operative radiotherapy has to be discussed. Indeed, in the event of a tumoral regrowth the risk of visual worsening may be more important than the potential side effects of pituitary irradiation.

In our study, no true recurrence was observed. No recurrence was diagnosed in patients in whom MRI performed at 6, 12 and 24 months after surgery failed to detect a tumoral residue and so, radiotherapy would be pointless in these patients. Because MRI has only been available since 1990 in our department, the length of follow-up in our study is not sufficient to definitively conclude. In the absence of clinical or biological signs of recurrence, we suggest that MRI should be repeated at intervals of 3, 5 and 10 years after surgery to verify that the patient is truly free of recurrence.

In conclusion, we suggest a MRI protocol that includes, a pre-operative MRI, and a 4- to 6-, 12- and 24-month post-operative MRI scan for every patient. When no tumoral residue is seen on these post-operative MRIs, the probability of tumoral regrowth is very low in which case pituitary radiotherapy is useless. MRI should be repeated 3, 5 and 10 years after the surgery in order to verify the absence of late recurrence. In patients with post-operative tumoral residue, we suggest that MRI must be repeated yearly. Because of its potential complications, radiotherapy should be considered only when the tumoral regrowth is proven except where the adenomatous residue is voluminous and close to the optic nerves/chiasma.

References


www.eje.org


Received 30 August 2001
Accepted 1 October 2001